120
Views
6
CrossRef citations to date
0
Altmetric
Review

Recent advances in the therapy of renal cancer

&
Pages 233-242 | Published online: 24 Jan 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Stéphane Oudard, Jacques Medioni, Jorge Aylllon, Eduardo Barrascourt, Reza-Thierry Elaidi, José Balcaceres & Florian Scotte. (2009) Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 9:6, pages 705-717.
Read now

Articles from other publishers (5)

Aini Hyytiäinen, Wafa Wahbi, Otto Väyrynen, Kauko Saarilahti, Peeter Karihtala, Tuula Salo & Ahmed Al-Samadi. (2021) Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?. Frontiers in Oncology 11.
Crossref
Anja Derer, Lisa Deloch, Yvonne Rubner, Rainer Fietkau, Benjamin Frey & Udo S. Gaipl. (2015) Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications. Frontiers in Immunology 6.
Crossref
Venumadhav Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das & Amit Verma. (2009) Mechanism of action of lenalidomide in hematological malignancies. Journal of Hematology & Oncology 2:1.
Crossref
Ningyan Zhang, Brent R. Williams, Ping Lu, Zhiqiang An & Chen-Ni Chin. 2009. Therapeutic Monoclonal Antibodies. Therapeutic Monoclonal Antibodies 711 762 .
Elena Benincasa, Alessandra Conti, Giandominik Bossone, Domenico Antonio Pasquale Gallà, Antonio Gianciotta, Stefano Maria Zuccaro & Raffaele Madaio. (2018) A Case of Complete Clinical Response with Sorafenib in a Patient with Thyroid Gland Metastases from Renal Cell Carcinoma 17 Years from Diagnosis. Tumori Journal 95:3, pages 403-403.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.